Sotatercept safe and effective across cardiac index groups

PHA Canada
Dec 18, 2024
1 min read

Cardiac index (CI) assesses the output of someone's heart based on their size. It measures heart function relative to the person's size (litres per minute per square metre), instead of just cardiac output (litres per minute). A study looked at data from both the PULSAR and STELLAR trials for sotatercept and found that, compared to placebo, sotatercept improved 6-minute walk distance consistently and was equally safe for people in all cardiac index groups.

Click here to read the paper in the Journal of Heart and Lung Transplantation

Recent Posts

Sotatercept vs. selexipag in severe PAH

Researchers used AI to indirectly compare data from three randomized controlled trials looking at sotatercept or selexipag in pulmonary arterial hypertension (PAH). Their findings suggest that sotater

Screening for PH in ILD

This study looked at how to better detect pulmonary hypertension (PH) in people with interstitial lung disease (ILD), since PH often makes breathing problems, quality of life, and survival worse. Rese

Biomarkers identified for high-altitude PH

This study looked at which proteins and metabolic biomarkers might be associated with the development of high-altitude pulmonary hypertension (PH). Looking at data from China, from rat tissues, and fr

Comments